ReviewMedicine and pharmacy reports2021
Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold.
Review in Medicine and pharmacy reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Nasal sprays and a behavioural intervention for respiratory tract infections in primary care: 12-month follow-up of a randomised open-label trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Trial
- Decongestant Effect of "Coldamaris Akut", a Carrageenan- and Sorbitol-Containing Nasal Spray in Seasonal Allergic Rhinitis.International journal of general medicine · 2024Trial
- Article
- Patient conversations that matter: assessing the role of TARGET TYI leaflets for respiratory care in England's community pharmacies.JAC-antimicrobial resistance · 2025Article
- The 2023 Garrod Lecture: Antimicrobial use and stewardship in primary care: what works, and what next?The Journal of antimicrobial chemotherapy · 2025Article
- A qualitative process evaluation of a nasal spray intervention to prevent respiratory tract infections.PloS one · 2025Article
- Holistic care in mild upper respiratory tract infections (MURTIs): an approach to individualized care management.Drugs in context · 2025Review
- Safety in Rats of a Novel Nasal Spray Formulation for the Prevention of Airborne Viral Infections.Pharmaceutics · 2023Article
- Common cold.Frontiers in allergy · 2023Review
- Article
- Article
- Iota-carrageenan extracted from red algae is a potent inhibitor of SARS-CoV-2 infection in reconstituted human airway epithelia.Biochemistry and biophysics reports · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The common cold is one of the most frequent viral infections in humans. Although benign, its symptoms result in economic burden and can lead to severe or even fatal complications in children, elderly and groups with comorbidities. The main purpose of the treatment is the relief of symptoms; however, the medication is often associated with adverse effects. Iota-carrageenan is a polysaccharide that reveals antiviral activity by binding to viruses, inhibiting its replications and, consequently, its viral propagation. This systematic review of the literature aims to compare the effectiveness of an iota-carrageenan nasal spray to placebo. This systematic review was conducted through research in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.